Lupin Pharmaceuticals, Inc.

Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited, an Indian multinational pharmaceutical company. Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to advancing healthcare by delivering high-quality, branded, and generic medications to patients and healthcare professionals across the United States. The company's mission aligns with its parent's global commitment to innovation, research, and accessible medicines.

The company's extensive product portfolio includes over 193 drugs marketed in the United States, encompassing both branded and generic formulations. Lupin Pharmaceuticals, Inc. focuses on a wide range of therapeutic areas, including cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infectives, and women's health. Its offerings also extend to biosimilars, over-the-counter drugs, and active pharmaceutical ingredients (APIs).

As a key part of Lupin Limited, which ranks among the top five pharmaceutical companies in India, Lupin Pharmaceuticals, Inc. contributes significantly to its parent's global market positioning. Lupin Limited is recognized as the 3rd largest in the U.S. by prescriptions and the 14th largest generics company globally by sales as of FY25. Recent developments for the company include FDA approvals for various medications, such as Solosec (secnidazole) for bacterial vaginosis and trichomoniasis. The leadership team, including Vinita Gupta (CEO) and Nilesh Gupta (MD) of the parent company, drives the company's continuous expansion and strengthening of its global pharmaceutical market presence.